Arcturus Therapeutics Holdings Inc.
ARCT
$6.72
$0.172.60%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -46.14% | -39.15% | -25.47% | 15.38% | -8.69% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -46.14% | -39.15% | -25.47% | 15.38% | -8.69% |
| Cost of Revenue | -42.50% | -30.04% | -26.28% | 21.70% | 36.28% |
| Gross Profit | 29.55% | -22.90% | 29.96% | -60.10% | -281.60% |
| SG&A Expenses | -12.77% | -16.09% | -10.82% | -8.66% | -0.09% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -36.17% | -26.98% | -23.04% | -8.93% | 1.21% |
| Operating Income | 20.29% | 2.73% | 18.57% | 33.47% | -22.33% |
| Income Before Tax | 18.73% | -6.94% | 14.46% | 34.82% | -190.23% |
| Income Tax Expenses | 100.00% | -100.00% | -115.80% | -117.67% | -100.16% |
| Earnings from Continuing Operations | 18.73% | -6.49% | 16.39% | 36.44% | -172.30% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 18.73% | -6.49% | 16.39% | 36.44% | -172.30% |
| EBIT | 20.29% | 2.73% | 18.57% | 33.47% | -22.33% |
| EBITDA | 20.50% | 2.36% | 19.15% | 34.51% | -22.43% |
| EPS Basic | 20.51% | -5.70% | 17.20% | 37.31% | -168.80% |
| Normalized Basic EPS | 20.52% | -6.15% | 15.28% | 35.71% | -29.06% |
| EPS Diluted | 20.51% | -5.53% | 17.31% | 37.36% | -158.39% |
| Normalized Diluted EPS | 20.52% | -6.15% | 15.28% | 35.71% | -28.28% |
| Average Basic Shares Outstanding | 1.51% | 0.83% | 1.17% | 1.40% | 1.49% |
| Average Diluted Shares Outstanding | 1.51% | 0.83% | 1.17% | 1.40% | 0.93% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |